Mylan Inc. company logo

# RNN 1st Gen Model Mylan Inc. Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
Feb. 22, 2018
Deal entry on
Feb. 22, 2018
0.44%Expected margin
69.14% successful of 81 deals
$ 41.21 Last close price
at 21-feb-2018

MYL

Model's trade recommendations -2.35% Return for period

1.46% Annual return

$22.18B Market Cap

β 1.35  

MYL

Model (following trade recommendations)

MYL

Underlying stock

S&P 500

Index
Return for period -2.35%
-10.65%
1.78%
52wk return -5.49%
-1.88%
16.82%
52wk Range
29.63—47.62
2000.54—2399.63
Sortino ratio 0.18
Sharpe ratio 0.16
Norm. RMSE 1.07%
Downside risk 14.88%
Volatility 17.29%
  • BUY Analysts consensus recommendation

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Mylan Inc. (MYL) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MYL model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 533M
P/E 8.80
Shares Outstanding 536M
% Held by Insiders 0.69%
% Held by Institutions 76.86%
EPS (last reported FY) $4.89
EPS (last reported Q) $1.10
EPS, estimated (last reported Q) $1.22
Total revenues $11 B
Net income $0 B